Rebecca Benner

1.6k total citations
22 papers, 1.2k citations indexed

About

Rebecca Benner is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Rebecca Benner has authored 22 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Hematology and 4 papers in Molecular Biology. Recurrent topics in Rebecca Benner's work include Acute Myeloid Leukemia Research (6 papers), Lung Cancer Treatments and Mutations (4 papers) and Lung Cancer Research Studies (3 papers). Rebecca Benner is often cited by papers focused on Acute Myeloid Leukemia Research (6 papers), Lung Cancer Treatments and Mutations (4 papers) and Lung Cancer Research Studies (3 papers). Rebecca Benner collaborates with scholars based in United States, France and United Kingdom. Rebecca Benner's co-authors include Michael W. Dunne, Marian R. Fisher, Thomas D. Cook, Christopher M. O’Connor, Sandeep Gupta, Louis Yao, Marc A. Pfeffer, Joseph B. Muhlestein, Arthur T. DeGaetano and Maciej Krzakowski and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Blood.

In The Last Decade

Rebecca Benner

22 papers receiving 1.2k citations

Peers

Rebecca Benner
Cindy McGrath United States
M Kashimura Japan
Toru Takahashi Japan
Paramjit Kaur India
Han Vorng France
Juliana Pereira Brazil
Hugo Sousa Portugal
Shuji Tohda Japan
Estelle Seillès France
Heiko Rühl Germany
Cindy McGrath United States
Rebecca Benner
Citations per year, relative to Rebecca Benner Rebecca Benner (= 1×) peers Cindy McGrath

Countries citing papers authored by Rebecca Benner

Since Specialization
Citations

This map shows the geographic impact of Rebecca Benner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rebecca Benner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rebecca Benner more than expected).

Fields of papers citing papers by Rebecca Benner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rebecca Benner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rebecca Benner. The network helps show where Rebecca Benner may publish in the future.

Co-authorship network of co-authors of Rebecca Benner

This figure shows the co-authorship network connecting the top 25 collaborators of Rebecca Benner. A scholar is included among the top collaborators of Rebecca Benner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rebecca Benner. Rebecca Benner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Montesinos, Pau, Vamsi Kota, Joseph Brandwein, et al.. (2023). A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia. Cancer Chemotherapy and Pharmacology. 91(5). 441–446. 5 indexed citations
2.
Liebert, Jeffrey, Rebecca Benner, Rachel Bezner Kerr, et al.. (2022). Farm size affects the use of agroecological practices on organic farms in the United States. Nature Plants. 8(8). 897–905. 32 indexed citations
3.
4.
Pautas, Cécile, Emmanuel Raffoux, Juliette Lambert, et al.. (2021). Outcomes following hematopoietic stem cell transplantation in patients treated with standard chemotherapy with or without gemtuzumab ozogamicin for acute myeloid leukemia. Bone Marrow Transplantation. 56(6). 1474–1477. 13 indexed citations
5.
6.
7.
Lambert, Juliette, Cécile Pautas, Christine Terré, et al.. (2018). Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica. 104(1). 113–119. 237 indexed citations
8.
Pautas, Cécile, Emmanuel Raffoux, Juliette Lambert, et al.. (2018). Outcomes Following Hematopoietic Stem Cell Transplantation in Patients Treated with Chemotherapy with or without Gemtuzumab Ozogamicin for Acute Myeloid Leukemia. Blood. 132(Supplement 1). 28–28. 5 indexed citations
9.
Langer, Corey J., Silvia Novello, Keunchil Park, et al.. (2014). Randomized, Phase III Trial of First-Line Figitumumab in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 32(19). 2059–2066. 124 indexed citations
10.
Belani, Chandra P., John Nemunaitis, Abraham Chachoua, et al.. (2013). Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer. Cancer Biology & Therapy. 14(7). 557–563. 31 indexed citations
11.
Manegold, C., Nico van Zandwijk, A. Szczęsna, et al.. (2011). A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Annals of Oncology. 23(1). 72–77. 117 indexed citations
12.
Hirsh, Vera, Luis Paz‐Ares, Michael Boyer, et al.. (2011). Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 29(19). 2667–2674. 116 indexed citations
13.
Goff, Laura W., Al B. Benson, Patricia LoRusso, et al.. (2010). Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine. Investigational New Drugs. 30(1). 290–298. 11 indexed citations
14.
Readett, David, et al.. (2007). PD3-1-6: PF-3512676 (CPG 7909), a toll-like receptor 9 agonist-status of development for non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 2(8). S461–S461. 5 indexed citations
15.
Chandra, Richa, Ping Liu, Jeanne D. Breen, et al.. (2007). Clinical Pharmacokinetics and Gastrointestinal Tolerability of a Novel Extended-Release Microsphere Formulation of Azithromycin. Clinical Pharmacokinetics. 46(3). 247–259. 25 indexed citations
16.
Aguilar, David, Marian R. Fisher, Christopher M. O’Connor, et al.. (2006). Metabolic syndrome, C-reactive protein, and prognosis in patients with established coronary artery disease. American Heart Journal. 152(2). 298–304. 34 indexed citations
17.
Cook, Thomas D., Rebecca Benner, & Marian R. Fisher. (2006). The WIZARD Trial as a Case Study of Flexible Clinical Trial Design. Drug Information Journal. 40(3). 345–353. 5 indexed citations
18.
Dunne, Michael W., Neeru Singh, Manmohan Shukla, et al.. (2005). A Multicenter Study of Azithromycin, Alone and in Combination with Chloroquine, for the Treatment of Acute UncomplicatedPlasmodium falciparumMalaria in India. The Journal of Infectious Diseases. 191(10). 1582–1588. 74 indexed citations
19.
O’Connor, Christopher M., Michael W. Dunne, Marc A. Pfeffer, et al.. (2003). Azithromycin for the Secondary Prevention of Coronary Heart Disease Events. JAMA. 290(11). 1459–1459. 227 indexed citations
20.
Fessel, Jeffrey, Princy Kumar, P. Keiser, et al.. (2000). A Randomized, Double-Blind Trial Comparing Azithromycin and Clarithromycin in the Treatment of Disseminated Mycobacterium avium Infection in Patients with Human Immunodeficiency Virus. Clinical Infectious Diseases. 31(5). 1245–1252. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cindy McGrath Breakdown of academic impact, for papers by M Kashimura Breakdown of academic impact, for papers by Toru Takahashi Breakdown of academic impact, for papers by Paramjit Kaur Breakdown of academic impact, for papers by Han Vorng Breakdown of academic impact, for papers by Juliana Pereira Breakdown of academic impact, for papers by Hugo Sousa Breakdown of academic impact, for papers by Shuji Tohda Breakdown of academic impact, for papers by Estelle Seillès Breakdown of academic impact, for papers by Heiko Rühl
Rankless by CCL
2026